Hyperglycemia and Diabetes Mellitus Following Organ Transplantation

Current Diabetes Reports

Volumn 16, Issue 2, 2016, Pages 1-11

  Galindo, Rodolfo J ^a   Wallia, Amisha ^b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Diabetes mellitus; Hyperglycemia; New onset diabetes after transplantation; Organ transplantation; Outcomes; Post transplant diabetes

Indexed keywords

INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; LINAGLIPTIN; SITAGLIPTIN; IMMUNOSUPPRESSIVE AGENT;

CRITICALLY ILL PATIENT; DIABETES MELLITUS; DIAGNOSTIC TEST; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; GLYCEMIC CONTROL; HEART TRANSPLANTATION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; INCIDENCE; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MORBIDITY; NEW ONSET DIABETES AFTER TRANSPLANTATION; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT CARE; POSTTRANSPLANTATION DIABETES MELLITUS; REVIEW; SURGICAL MORTALITY; ADVERSE EFFECTS; DIABETES MELLITUS, TYPE 2; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE AGENTS; INSULIN; ORGAN TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84955455788     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-015-0707-1     Document Type: Review

References (91)

1. Chakkera HA, Weil EJ, Castro J, et al. Hyperglycemia during the immediate period after kidney transplantation. Clin J Am Soc Nephrol. 2009;4:853–9.
2. Thomas MC, Moran J, Mathew TH, et al. Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes. BMC Nephrol. 2000;1:1.
3. First MR, Dhadda S, Croy R, et al. New-onset diabetes after transplantation (nodat): an evaluation of definitions in clinical trials. Transplantation. 2013;96:58–64.
4. Sharif A, Hecking M, de Vries AP, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 2014;14:1992–2000. This article represents the most recent updated guidelines regarding the diagnosis and treatment of post-transplant diabetes mellitus. The consensus meeting was held in September 8-9th, 2013.
5. Umpierrez GE, Isaacs SD, Bazargan N, et al. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metabol. 2002;87:978–82.
6. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359–67.
7. NICE-SUGAR Study Investigators et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283–97.
8. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation. 2003;75:SS3–24.
9. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2015;38:S8–S16.
10. Shabir S, Jham S, Harper L, et al. Validity of glycated haemoglobin to diagnose new onset diabetes after transplantation. Transpl Int. 2013;26:315–21.
11. Hecking M, Werzowa J, Haidinger M, et al. Novel views on new-onset diabetes after transplantation: development, prevention and treatment. Nephrol Dial Transplant. 2013;28:550–66.
12. Hecking M, Kainz A, Werzowa J, et al. Glucose metabolism after renal transplantation. Diabetes Care. 2013;36:2763–71.
13. Pham PT, Pham PC, Lipshutz GS, et al. New onset diabetes mellitus after solid organ transplantation. Endocrinol Metab Clin N Am. 2007;36:873–90.
14. Midtvedt K, Hartmann A, Hjelmesaeth J, et al. Insulin resistance is a common denominator of post-transplant diabetes mellitus and impaired glucose tolerance in renal transplant recipients. Nephrol Dial Transplant. 1998;13:427–31.
15. Bayes B, Granada ML, Pastor MC, et al. Obesity, adiponectin and inflammation as predictors of new-onset diabetes mellitus after kidney transplantation. Am J Transplant. 2007;7:416–22.
16. van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Investig. 2009;39:81–93.
17. Chakkera HA, Mandarino LJ. Calcineurin inhibition and new-onset diabetes mellitus after transplantation. Transplantation. 2013;95:647–52.
18. Araki M, Flechner SM, Ismail HR, et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mtor inhibitor drugs. Transplantation. 2006;81:335–41.
19. Soleimanpour SA, Crutchlow MF, Ferrari AM, et al. Calcineurin signaling regulates human islet beta-cell survival. J Biol Chem. 2010;285:40050–9.
20. Barlow AD, Nicholson ML, Herbert TP. Evidence for rapamycin toxicity in pancreatic β-cells and a review of the underlying molecular mechanisms. Diabetes. 2013;62:2674–82.
21. Masson P, Henderson L, Chapman JR, et al. Belatacept for kidney transplant recipients. Cochrane Database Syst Rev. 2014;11:CD010699.
22. Hackman KL, Snell GI, Bach LA. Prevalence and predictors of diabetes after lung transplantation: a prospective, longitudinal study. Diabetes Care. 2014;37:2919–25. This prospective longitudinal study evaluated glycemic status pre- and post-lung transplantation with the use of frequent oral glucose tolerance testing over time.
23. Hecking M, Haidinger M, Döller D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol. 2012;23:739–49.
24. Lund LH, Edwards LB, Kucheryavaya AY, et al. The registry of the international society for heart and lung transplantation: thirtieth official adult heart transplant report--2013; focus theme: age. J Heart Lung Transplant. 2013;32:951–64.
25. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 annual data report: kidney. Am J Transplant. 2014;14 Suppl 1:11–44.
26. Chakkera HA, Knowler WC, Devarapalli Y, et al. Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus. Clin J Am Soc Nephrol. 2010;5:1669–75.
27. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178–85.
28. Yadav AD, Chang YH, Aqel BA, et al. New onset diabetes mellitus in living donor versus deceased donor liver transplant recipients: analysis of the UNOS/OPTN database. J Transplant. 2013;2013:269096.
29. Kuo HT, Sampaio MS, Ye X, et al. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database. Transplantation. 2010;89:1134–40.
30. Saraiva J, Sola E, Prieto D, et al. Diabetes as an outcome predictor after heart transplantation. Interact Cardiovasc Thorac Surg. 2011;13:499–504.
31. Ye X, Kuo HT, Sampaio MS, et al. Risk factors for development of new-onset diabetes mellitus in adult heart transplant recipients. Transplantation. 2010;89:1526–32.
32. Ollech JE, Kramer MR, Peled N, et al. Post-transplant diabetes mellitus in lung transplant recipients: incidence and risk factors. Eur J Cardiothorac Surg. 2008;33:844–8.
33. Montori VM, Basu A, Erwin PJ, et al. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care. 2002;25:583–92.
34. Cosio FG, Pesavento TE, Kim S, et al. Patient survival after renal transplantation: impact of post-transplant diabetes. Kidney Int. 2002;62:1440–6.
35. Thomas MC, Mathew TH, Russ GR, et al. Early peri-operative glycaemic control and allograft rejection in patients with diabetes mellitus: a pilot study. Transplantation. 2001;72:1321–4.
36. Cosio FG, Kudva Y, van der Velde M, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int. 2005;67:2415–21.
37. Burroughs TE, Swindle J, Takemoto S, et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation. 2007;83:1027–34.
38. Hermayer KL, Egidi MF, Finch NJ, et al. A randomized controlled trial to evaluate the effect of glycemic control on renal transplantation outcomes. J Clin Endocrinol Metabol. 2012;97:4399–406. This study is a randomized controlled clinical trial in the renal transplant population evaluating a subcutaneous vs. intravenous insulin therapy regimen, showing no difference in delayed graft function, but increased hypoglycemia in the IV insulin therapy group.
39. Li P, Hunt KJ, Taber DJ, et al. Inflammatory biomarkers, glycemic variability, hypoglycemia, and renal transplant outcomes: results of a randomized controlled trial. Transplantation. 2014;98:632–9.
40. Matas AJ, Gillingham KJ, Elick BA, et al. Risk factors for prolonged hospitalization after kidney transplants. Clin Transpl. 1997;11:259–64.
41. Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant. 2003;3:590–8.
42. Moon JI, Barbeito R, Faradji RN, et al. Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: long-term follow up. Transplantation. 2006;82:1625–8.
43. Ammori JB, Sigakis M, Englesbe MJ, et al. Effect of intraoperative hyperglycemia during liver transplantation. J Surg Res. 2007;140:227–33.
44. Darstein F, Konig C, Hoppe-Lotichius M et al. New onset of diabetes after transplantation is associated with improved patient survival after liver transplantation due to confounding factor. Eur J Intern Med. 2015.
45. Wallia A, Parikh ND, Molitch ME, et al. Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. Transplantation. 2010;89:222–6.
46. Park C, Hsu C, Neelakanta G, et al. Severe intraoperative hyperglycemia is independently associated with surgical site infection after liver transplantation. Transplantation. 2009;87:1031–6.
47. Wallia A, Parikh N, O’Shea-Mahler E, et al. Glycemic control by a glucose management service and infection rates after liver transplantation. Endocr Pract. 2011;17:546–51.
48. Hoehn RS, Singhal A, Wima K, et al. Effect of pretransplant diabetes on short-term outcomes after liver transplantation: a national cohort study. Liver Int. 2015;35:1902–9.
49. Axelrod DA, Dzebisashvili N, Lentine K, et al. Assessing variation in the costs of care among patients awaiting liver transplantation. Am J Transplant. 2014;14:70–8.
50. Marelli D, Laks H, Patel B, et al. Heart transplantation in patients with diabetes mellitus in the current era. J Heart Lung Transplant. 2003;22:1091–7.
51. Kilic A, Weiss ES, George TJ, et al. What predicts long-term survival after heart transplantation? An analysis of 9,400 ten-year survivors. Ann Thorac Surg. 2012;93:699–704.
52. Higgins J, Pflugfelder PW, Kostuk WJ. Increased morbidity in diabetic cardiac transplant recipients. Can J Cardiol. 2009;25:e125–9.
53. Russo MJ, Chen JM, Hong KN, et al. Survival after heart transplantation is not diminished among recipients with uncomplicated diabetes mellitus: an analysis of the United Network of Organ Sharing database. Circulation. 2006;114:2280–7.
54. Lang CC, Beniaminovitz A, Edwards N, et al. Morbidity and mortality in diabetic patients following cardiac transplantation. J Heart Lung Transplant. 2003;22:244–9.
55. Garcia C, Wallia A, Gupta S, et al. Intensive glycemic control after heart transplantation is safe and effective for diabetic and non-diabetic patients. Clin Transpl. 2013;27:444–54.
56. Yusen RD, Christie JD, Edwards LB, et al. The registry of the international society for heart and lung transplantation: thirtieth adult lung and heart-lung transplant report--2013; focus theme: age. Am J Transplant. 2013;32:965–78.
57. Hackman KL, Bailey MJ, Snell GI, et al. Diabetes is a major risk factor for mortality after lung transplantation. Am J Transplant. 2014;14:438–45.
58. Bradbury RA, Shirkhedkar D, Glanville AR, et al. Prior diabetes mellitus is associated with increased morbidity in cystic fibrosis patients undergoing bilateral lung transplantation: an ‘orphan’ area? A retrospective case–control study. Intern Med J. 2009;39:384–8.
59. Hofer M, Schmid C, Benden C, et al. Diabetes mellitus and survival in cystic fibrosis patients after lung transplantation. J Cyst Fibros. 2012;11:131–6.
60. Hayes D, Jr., Patel AV, Black SM et al. Influence of diabetes on survival in patients with cystic fibrosis before and after lung transplantation. J Thorac Cardiovasc Surg. 2015.
61. Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol. 2012;97:16–38.
62. Jacobi J, Bircher N, Krinsley J, et al. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. Crit Care Med. 2012;40:3251–76.
63. American Diabetes Association. Diabetes care in the hospital, nursing home, and skilled nursing facility. Diabetes Care. 2015;38:S80–5.
64. Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32:1119–31.
65. Umpierrez G, Cardona S, Pasquel F, et al. Randomized controlled trial of intensive versus conservative glucose control in patients undergoing coronary artery bypass graft surgery: GLUCO-CABG trial. Diabetes Care. 2015;38:1665–72.
66. Desai K, Gandhi G, Shoraka A et al. Outcomes with intensive glycemic control in liver transplantation: a randomized controlled trial [abstract]. Diabetes. 2015;64 (suppl 1).
67. Wallia A, Gupta S, Garcia C, et al. Examination of implementation of intravenous and subcutaneous insulin protocols and glycemic control in heart transplant patients. Endocr Pract. 2014;20:527–35.
68. Keegan MT, Vrchota JM, Haala PM, et al. Safety and effectiveness of intensive insulin protocol use in post-operative liver transplant recipients. Transplant Proc. 2010;42:2617–24.
69. Gupta S, Oakes DJ, Therasse A et al. Extreme insulin resistance following heart transplant. In: Boris Draznin, editor. Diabetes Case Studies: Real Problems, Practical Solutions. American Diabetes Association; 2015. 214–7
70. Schmeltz LR, DeSantis AJ, Schmidt K, et al. Conversion of intravenous insulin infusions to subcutaneously administered insulin glargine in patients with hyperglycemia. Endocr Pract. 2006;12:641–50.
71. Dungan K, Hall C, Schuster D, et al. Differential response between diabetes and stress-induced hyperglycaemia to algorithmic use of detemir and flexible mealtime aspart among stable postcardiac surgery patients requiring intravenous insulin. Diabetes Obes Metab. 2011;13:1130–5.
72. Dickerson RN, Wilson VC, Maish GO, et al. Transitional nph insulin therapy for critically ill patients receiving continuous enteral nutrition and intravenous regular human insulin. JPEN J Parenter Enteral Nutr. 2013;37:506–16.
73. Baldwin D, Zander J, Munoz C, et al. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care. 2012;35:1970–4.
74. Burt MG, Roberts GW, Aguilar-Loza NR, et al. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metabol. 2011;96:1789–96.
75. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract. 2009;15:469–74.
76. Seggelke SA, Gibbs J, Draznin B. Pilot study of using neutral protamine hagedorn insulin to counteract the effect of methylprednisolone in hospitalized patients with diabetes. J Hosp Med. 2011;6:175–6.
77. Dhital SM, Shenker Y, Meredith M, et al. A retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone-associated diabetes mellitus in hospitalized patients. Endocr Pract. 2012;18:712–9.
78. Kreider KE, Lien LF. Transitioning safely from intravenous to subcutaneous insulin. Curr Diab Rep. 2015;15:23.
79. Umpierrez GE, Schwartz S. Use of incretin-based therapy in hospitalized patients with hyperglycemia. Endocr Pract. 2014;20:933–44.
80. van Raalte DH, van Genugten RE, Linssen MM, et al. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care. 2011;34:412–7.
81. Umpierrez GE, Gianchandani R, Smiley D, et al. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. Diabetes Care. 2013;36:3430–5.
82. Umpierrez GE, Reyes D, Smiley D, et al. Hospital discharge algorithm based on admission HbA1c for the management of patients with type 2 diabetes. Diabetes Care. 2014;37:2934–9.
83. Wallia A, Molitch ME. Insulin therapy for type 2 diabetes mellitus. JAMA. 2014;311:2315–25.
84. Therasse A, Wallia A, Molitch ME. Management of post-transplant diabetes. Curr Diab Rep. 2013;13:121–9.
85. American Diabees Association. Glycemic targets. Diabetes Care. 2015;38:S33–40.
86. U.S. Renal Data System Annual Data. Medications for diabetes control in the first six months post-transplant, 2009–2011. Atlas of chronic kidney disease and end-stage renal disease in the United States, 2013.
87. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1121–7.
88. Biesenbach G, Raml A, Schmekal B, et al. Decreased insulin requirement in relation to gfr in nephropathic type 1 and insulin-treated type 2 diabetic patients. Diabet Med. 2003;20:642–5.
89. Sharif A, Moore R, Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation. 2008;85:353–8.
90. Alexander JW, Metze TJ, McIntosh MJ, et al. The influence of immunomodulatory diets on transplant success and complications. Transplantation. 2005;79:460–5.
91. Chakkera HA, Weil EJ, Pham PT, et al. Can new-onset diabetes after kidney transplant be prevented? Diabetes Care. 2013;36:1406–12.